Inventor · disambiguated record
Liat Hayardeny
Also filed as: HAYARDENY LIAT
2 granted patents·19 pending applications·7 citations·filing 2003–2017
54Inventor score
Top patents by PatentIndex Score
21 records- 0180US9702007B2Genetic markers predictive of response to glatiramer acetateTCHELET AMIR·Filed 2014·Granted Jul 11, 2017·6 cites·20 claims
- 0263US2014271532A1Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosisKREITMAN RIVKA·Filed 2014·Application pending·0 cites
- 0357US2017354651A1Treatment Of Neurodegenerative Diseases With Combination Of Laquinimod And FingolimodHAYDEN MICHAEL·Filed 2017·Application pending·0 cites
- 0456US9585878B2Treatment of BDNF-related disorders using laquinimodHAYARDENY LIAT·Filed 2010·Granted Mar 7, 2017·1 cites·10 claims
- 0556US2017224674A1Treatment Of Neurodegenerative Diseases With Combination Of Laquinimod And FingolimodHAYDEN MICHAEL·Filed 2017·Application pending·0 cites
- 0655US2012027718A1Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosisKREITMAN RIVKA·Filed 2011·Application pending·0 cites
- 0753US2010167983A1Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosisTEVA PHARMA·Filed 2010·Application pending·0 cites
- 0852US2016074380A1Treatment Of Neurodegenerative Diseases With Combination Of Laquinimod And FingolimodHAYDEN MICHAEL·Filed 2015·Application pending·0 cites
- 0946US2018002753A1Genetic markers predictive of response to glatiramer acetateTCHELET AMIR·Filed 2017·Application pending·0 cites
- 1045US2010285600A1Markers associated with the therapeutic efficacy of glatiramer acetateTEVA PHARMA·Filed 2010·Application pending·0 cites
- 1143US2014235670A1Treatment of progressive forms of multiple sclerosis with laquinimodTARCIC NORA·Filed 2014·Application pending·0 cites
- 1242US2007037740A1Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosisPINCHASI IRIT·Filed 2004·Application pending·0 cites
- 1341US2016201132A1Gene expression biomarkers of laquinimod responsivenessTEVA PHARMA·Filed 2014·Application pending·0 cites
- 1440US2018064702A1Treatment of progressive forms of multiple sclerosis with laquinimodTARCIC NORA·Filed 2017·Application pending·0 cites
- 1539US2004176430A1Propargyl-trifluoromethoxy-amino-benzothiazole derivativesFiled 2003·Application pending·0 cites
- 1638US2008261894A1Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple SclerosisKREITMAN RIVKA·Filed 2006·Application pending·0 cites
- 1738US2006240463A1Markers associated with the therapeutic efficacy of glatiramer acetateTEVA PHARMA·Filed 2006·Application pending·0 cites
- 1837US2017239234A1Treatment of bdnf-related disorders using laquinimodHAYARDENY LIAT·Filed 2017·Application pending·0 cites
- 1934US2016243103A1Treatment of BDNF-Related Disorders Using LaquinimodHAYARDENY LIAT·Filed 2016·Application pending·0 cites
- 2032US2007244056A1Combination Therapy With Glatiramer Acetate and RiluzoleHAYARDENY LIAT·Filed 2005·Application pending·0 cites
- 2126US2017003277A1Biological characterization of a glatiramer acetate related drug product using mammalian and human cellsHAYDEN MICHAEL·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Liat Hayardeny files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →